Discover
MNPR
Monopar Therapeutics Inc.
95.03
2 x 95.95
1 x 96.95
bid
ask
+
2.44
2.64%
2 @ 04:00 PM
95.03 +0.00 (0.00%)
| Ytd | 45.53% | |
| 1y | 183.16% |
93.75
day range
100.33
29.18
52 week range
105.00
| Open | 93.83 | Prev Close | 92.59 | Low | 93.75 | High | 100.33 | Mkt Cap | 636.61M |
| Vol | 176.91K | Avg Vol | 171.61K | EPS | -1.93 | P/E | N/A | Forward P/E | -10.17 |
| Beta | 1.10 | Short Ratio | 0.15 | Inst. Own | 24.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 64.05 | 200-d Avg | 68.35 | 1yr Est | 27.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-08 | 2024-09 | -0.46 | -0.37 | 0.09 | 19.57% |
| 2024-08-09 | 2024-06 | -0.45 | -0.5 | -0.05 | -11.11% |
| 2024-08-09 | 2024-06 | -0.45 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.85 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.85 | -0.5 | 0.35 | 41.18% |
| 2024-03-28 | 2023-12 | -0.85 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-11 | JonesTrading | Upgrade | Hold | Buy |
| 2023-06-01 | HC Wainwright & Co. | Upgrade | Buy | |
| 2023-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-12-28 | ANDERSON RAYMOND WILLIAM | Director | 26.86K | Conversion of Exercise of derivative security |
| 2023-12-28 | BROWN MICHAEL J | Director | 4.51M | Conversion of Exercise of derivative security |
| 2024-06-27 | CITTADINE ANDREW | Chief Operating Officer | 193.07K | Conversion of Exercise of derivative security |
| 2023-12-28 | KLAUSNER ARTHUR J | Director | 3.09M | Conversion of Exercise of derivative security |
| 2019-12-17 | LEO KARL | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2022-03-30 | MAZAR ANDREW PAUL | Officer and Director | 4.30M | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Geode Capital Management, LLC | 14.07K | 337.58K | 0.27% |
| 2024-09-29 | Wells Fargo & Company | 500.00 | 12.00K | 0.01% |
| 2024-09-29 | NewEdge Advisors, LLC | 600.00 | 14.40K | 0.01% |
| 2024-09-29 | UBS Group AG | 512.00 | 12.29K | 0.01% |
| 2024-09-29 | Federation Des Caisses Desjardins Du Quebec | 16.00 | 384.00 | 0.00% |
| 2024-09-29 | Bank of America Corporation | 13.00 | 312.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Extended Market Index Fund | 9.03K | 216.82K | 0.17% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 9.02K | 216.58K | 0.17% |
| 2024-10-30 | Fidelity Total Market Index Fund | 5.24K | 125.78K | 0.10% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 2.62K | 62.90K | 0.05% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 2.69K | 64.56K | 0.05% |
Split
| Split | Date |
|---|---|
| 1 : 5 | 2024-08-13 |